跳到正文
Drug Discovery & Development· Julia Rock-Torcivia·· 7 天前精选AI 评分73

FDA要求所有GLP-1受体激动剂厂商在标签中加入NAION警示

FDA’s GLP-1 vision warning rests on mixed evidence

AI 导读

FDA周一要求所有GLP-1受体激动剂厂商在标签的警告与注意事项部分加入非动脉炎性前部缺血性视神经病变(NAION)警示,但未设为黑框警告。FDA的真实世界研究显示,2型糖尿病成人中该类药物的NAION风险较SGLT-2抑制剂无统计学显著升高,较DPP-4抑制剂高43%;126项试验汇总分析中GLP-1使用者为每10万人年6.4例,对照人群为3.8例。

推荐理由

文中将FDA审评数据与外部分歧研究并列,读者可据此判断这类监管决定的证据强度。

正文 · 原文

[Adobe Stock]

The FDA on Monday required all glucagon-like peptide-1 receptor agonist (GLP-1 RA) makers to add a warning about non-arteritic anterior ischemic optic neuropathy (NAION) to labels. The condition, also informally referred to as “eye stroke,” is a sudden, painless, often permanent vision loss in one eye, with no proven treatment. The FDA’s decision is based on a review of clinical trials, observational studies, animal data and case reports.

The FDA is requiring an update to the Warnings and Precautions section of the label, not a boxed warning. It tells clinicians to have patients report sudden vision changes right away, refer suspected cases to an ophthalmologist and “consider” stopping the drug if NAION develops, unless the benefits clearly outweigh the risk.

The warning is class-wide, but the evidence behind it is mixed and the absolute risk is small. The FDA’s real-world study of adults with type 2 diabetes found no statistically significant risk increase compared with sodium-glucose cotransporter-2 (SGLT-2) inhibitors, but a 43% higher risk than with dipeptidyl peptidase-4 (DPP-4) inhibitors.

What the trial data show

An analysis of 126 trials involving 134,253 GLP-1 users and comparison patients found 15 probable NAION events, 10 of them in GLP-1 users. That works out to 6.4 cases per 100,000 person-years among GLP-1 users versus 3.8 among comparison patients, an observed difference of 2.6 cases per 100,000 person-years. The FDA also cites a general-population rate of 2.3 to 10.2 cases per 100,000 adults over 50 per year, but that figure comes from a different population and isn’t directly comparable to the trial rates.

The FDA said its review of animal data found no mechanism, and that adverse event reports were hard to interpret because NAION risk factors, including diabetes and hypertension, are common among GLP-1 users.

According to the FDA, methodologically rigorous observational studies “consistently” showed increased risk in new GLP-1 users with type 2 diabetes compared with patients starting DPP-4 or SGLT-2 inhibitors.

Outside studies are split

Two Scandinavian studies involving type 2 diabetes patients on semaglutide (Ozempic, Wegovy) concluded that the drug was associated with increased risk of NAION. A study of U.S. health records in the TriNetX network that grouped users of semaglutide and tirzepatide (Mounjaro, Zepbound) together found 76% higher NAION risk than with other diabetes drugs. During follow-up of up to two years, researchers recorded 35 cases among 79,699 patients taking semaglutide or tirzepatide versus 19 among 79,699 comparison patients. The hazard ratio was 1.76, with a 95% confidence interval of 1.01–3.07.

A Cleveland Clinic study of about 220,000 GLP-1 users with type 2 diabetes, including about 120,000 on semaglutide, found no statistically significant increase in NAION risk.

The American Optometric Association has recommended a baseline eye exam to check optic nerve health for new GLP-1 users since 2025.

Companies can still contest the labeling language before the FDA finalizes it. Eli Lilly told USA Today in a statement that it is “carefully evaluating the update and will respond to the FDA promptly.” Novo Nordisk spokesperson Liz Skrbkova told the paper the company does not believe the data “establish a cause-and-effect relationship.” The company has listed NAION as a very rare side effect in EU leaflets since a 2025 European Medicines Agency review.

Lawsuits allege vision loss

As of Oct. 1, 247 cases were pending in the federal NAION multidistrict litigation. The suits against Novo Nordisk and Eli Lilly allege failure to warn of NAION.

In November 2025, Denmark’s patient compensation body, funded by the state and insurers, awarded four claimants a combined 800,000 Danish kroner (about $124,000). The patients said they developed NAION after taking Wegovy or Ozempic.


Filed Under: Ophthalmology
Tagged With: drug safety, Eli Lilly, eye stroke, FDA, GLP-1, Mounjaro, NAION, Novo Nordisk, Ozempic, semaglutide, Tirzepatide, Wegovy, Zepbound


来源:Drug Discovery & Development · drugdiscoverytrends.com